Daily one obscure US stock

$FDMT

【Personal Opinion】: A late-stage clinical-stage ophthalmic gene therapy Biotech. Its core product 4D-150 has already entered global Phase 3 clinical trials. Over the next 1.5 years, it will see multiple major data catalysts, making it a typical data-driven investment target. It’s suitable for those who want to track and weigh the “clinical progress” game, but it’s not suitable for building a heavy position for long-term holding.

Core Data

Stock price: $13.00, up 2.44% on the day. Intraday high: $13.40; low: $12.63.

Total market cap: approximately $695 million.

Q1 revenue: approximately $3 million. The company is still in the R&D stage and has no revenue from commercial products yet.

Cash on the books: As of the end of 2025, cash, cash equivalents, and marketable securities totaled approximately $514 million. Management expects the funds to support operations through the second half of 2028.

30-day average daily trading volume: approximately $13 million. Liquidity is average, typical of a small- to mid-cap Biotech.

Short interest data: As of mid-May 2026, short interest is approximately 12.08 million shares, with a short ratio of about 25%. Days to cover: 19.1 days. If future clinical data exceed expectations, a Short Squeeze situation cannot be ruled out.

My Judgment Logic

The company focuses on ophthalmic AAV gene therapy. Its core product 4D-150 targets large-market diseases such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). The goal is to reduce the frequency of frequent intravitreal injections for patients while maintaining efficacy—there is broad market space.

Currently, 4D-150 progress is continuing to exceed expectations:

✅ The global Phase 3 trial 4FRONT-1 has already completed patient enrollment ahead of schedule;

✅ The global Phase 3 trial 4FRONT-2 has also completed patient enrollment approximately 4 months ahead of schedule, indicating smooth clinical advancement;

✅ Previously, the company reached a strategic collaboration in the Asia-Pacific region with Otsuka (Otsuka). This not only provided funding support, but also helps with future commercialization plans.

Currently, the company has sufficient cash reserves, with relatively low short-term financing pressure. In the future, the key driver of the stock price will come more from clinical data rather than financial performance.

⚠️ Potential Risks

The biggest risk for Biotech still comes from clinical trials.

If PRISM or subsequent Phase 3 data show that efficacy and safety do not meet market expectations, the stock price could experience significant volatility.

In addition, competition in the ophthalmology space is fierce. Large pharmaceutical companies such as Regeneron and Roche have also deployed related products. Even if approvals are granted in the future, the company will still need to deal with market competition and commercialization execution risks.

Over the next 1.5 years, the company will continue to enter the phase of realizing clinical data. Every key milestone could become an important stock price catalyst, and it is also the core focus of market attention

.#Meta卖算力引发存储股大跌